In Conversation

“ For more than 30 years, we have continued to invest, introduce new technologies, and develop deep technical expertise within our workforce that we now deploy across… ”

“ Innovators should hold CDMOs to a high bar, and CDMOs need to step up ”

“ Innovation cannot stop at the laboratory door. It must extend to how therapies are developed, approved, and reimbursed ”

“ While there is still work to be done in the US biosimilar space, we are not going anywhere. ”

“ In partnership with NORD and others, patients can turn that lived experience into meaningful evidence that helps move research forward. ”

“ Every patient, every physician, every payer presents their own distinct challenges and requirements. ”

“ The assumption that gene therapies are inherently expensive, applicable only to rare diseases, and carry significant risk is rapidly becoming outdated ”

“ 70 percent of healthcare decisions are influenced by diagnostic results, yet we spend just 2.5 percent of our healthcare budget on them ”

“ Despite all the changes, the US remains the premier market for our investment and where much of our future success will depend ”

“ Legend is looking at all ways to bring CAR-T to more patients, including allogeneic, autologous, and in vivo approaches ”

“ Our next phase of evolution is moving from pure-play generics to something more complex across branded products, biosimilars, and NCEs ”

“ Health equity has to be built into the process from the beginning, not treated as an afterthought ”